Protagonist Therapeutics PTGX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.78M+109% | -$44.38M-12.8% | -$39.34M-13.1% | -$34.77M-198% | -$11.66M-109% | ||
| $407K+8.2% | $376K+4.2% | $361K+18.8% | $304K+27.2% | $239K+103% | ||
| $14.52M+35.7% | $10.7M+1.3% | $10.56M-3.2% | $10.91M-20.9% | $13.8M+51.8% | ||
| $3M— | $0-100% | $2.42M+545% | $375K-69.7% | $1.24M— | ||
| -$10.79M-300% | $5.41M— | —— | —— | -$11.82M-466% | ||
| $1.92M+425% | $365K— | $0-100% | $1.1M+15.7% | $948K— | ||
| -$2K— | —— | —— | $22.28M+445,540% | $5K— | ||
| -$3.27M+56.1% | -$7.44M-142% | -$3.08M+38.6% | -$5.01M+8.9% | -$5.5M— | ||
| —— | —— | —— | -$1.89M-136% | -$800K-149% | ||
| -$547K— | —— | -$581K— | —— | $341K— | ||
| -$48.94M— | —— | —— | —— | $125.36M— | ||
| $215K+49.3% | $144K+63.6% | $88K-89.2% | $813K+49.2% | $545K+75.8% | ||
| $68.97M-33.9% | $104.27M-35.3% | $161.12M+140% | $67.15M-68.6% | $214.04M+87.1% | ||
| $156.69M+2.3% | $153.23M+49.3% | $102.65M-16.4% | $122.78M+8.5% | $113.18M+6.8% | ||
| $90.89M— | —— | -$58.56M— | —— | -$94.4M-982% | ||
| $23.37M— | —— | $5.66M+93.5% | $2.93M-75.5% | $11.92M— | ||
| $23.37M+724% | $2.84M-49.9% | $5.66M+93.5% | $2.93M-74.4% | $11.44M+184% | ||
| $65.32M+345% | $14.68M— | —— | $28.96M-31.7% | $42.4M+225% | ||
| —— | $923.5K0.0% | $923.5K0.0% | $923.5K0.0% | $923.5K+141% | ||
| $1.03M-23.3% | $1.34M-20.7% | $1.68M-12.0% | $1.91M-16.4% | $2.29M-17.1% | ||
| $3M— | $0-100% | $2.42M+545% | $375K-69.7% | $1.24M— | ||
| —— | —— | —— | —— | $22.83M— | ||
| -$547K— | —— | -$581K— | —— | $341K— | ||
| -$10.79M-300% | $5.41M— | —— | —— | -$11.82M-466% | ||
| $1.92M+425% | $365K— | $0-100% | $1.1M+15.7% | $948K— | ||
| $53.54M+11,689% | -$462K— | —— | —— | -$165M-200% | ||
| $439K+27.2% | $345K+225% | $106K-81.3% | $568K-0.2% | $569K+36.1% | ||
| $156.69M+2.3% | $153.23M+49.3% | $102.65M-16.4% | $122.78M+8.5% | $113.18M+6.8% | ||
| —— | —— | —— | —— | —— | ||
| $23.37M+724% | $2.84M-49.9% | $5.66M+93.5% | $2.93M-75.5% | $11.92M+196% | ||
| —— | —— | —— | —— | $479K— | ||
| $110K— | —— | —— | $70K+112% | $33K— | ||
| -$547K— | —— | -$581K— | —— | $341K— | ||
| —— | $923.5K0.0% | $923.5K0.0% | $923.5K0.0% | $923.5K+141% | ||
| -$49.16M— | —— | —— | —— | $124.82M— | ||
| -$49.16M— | —— | —— | —— | $124.82M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Protagonist Therapeutics generate?
- Protagonist Therapeutics (PTGX) generated $317.6M in operating cash flow over the trailing twelve months.
- What is Protagonist Therapeutics's free cash flow?
- After $1.3M of capital expenditures, Protagonist Therapeutics's free cash flow was $316.6M over the trailing twelve months, up 364.9% year over year.
- Where does Protagonist Therapeutics's cash flow data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
